The Research Unit, Department of Palliative Medicine, Bispebjerg Hospital, Copenhagen University Hospital, Bispebjerg Bakke 23, DK-2400, Copenhagen, NV, Denmark.
Department of Public Health, University of Copenhagen, Copenhagen, Denmark.
Support Care Cancer. 2020 Apr;28(4):1725-1735. doi: 10.1007/s00520-019-04976-x. Epub 2019 Jul 11.
Patients in palliative care are willing to answer short questionnaires, like the EORTC QLQ-C15-PAL; however, patients may suffer from other symptoms and problems (S/Ps) not covered by such questionnaires. Therefore, to identify which other S/Ps patients experience, in addition to those already included in the EORTC QLQ-C15-PAL, we developed a brief instrument to supplement this questionnaire named WISP (Write In three Symptoms/Problems), permitting patients to report 1-3 additional S/Ps and their severity. We aim to investigate the nature, prevalence, and severity of S/Ps reported on WISP.
A register-based study with data obtained from the Danish Palliative Care Database. This study included adults with advanced cancer admitted to specialized palliative care in Denmark, who reported S/Ps on WISP. S/Ps were categorized qualitatively, and their prevalence and severity were calculated.
Of the 5447 patients who completed the EORTC QLQ-C15-PAL, 1788 (32.8%) reported at least one symptom/problem using WISP. In total, 2796 S/Ps were reported; 24.8% were already covered by EORTC QLQ-C15-PAL; 63.6% were new, 10.1% were diagnoses and 1.6% could not be coded. S/Ps already covered and new were grouped into 61 categories. The most prevalent S/Ps reported were (in decreasing order) pain, edema, dizziness, impaired physical or emotional function, cough, and sweats. Overall, 85% of the S/Ps were rated as moderate to severe.
The WISP instrument strongly improves the recognition of S/Ps by combining standardization with individualization. We recommend its use for comprehensive symptom assessment alongside the EORTC QLQ-C15-PAL, and potentially also alongside the EORTC QLQ-C30.
姑息治疗患者愿意回答简短的问卷,如 EORTC QLQ-C15-PAL;然而,患者可能会出现其他未被这些问卷涵盖的症状和问题(S/Ps)。因此,为了确定患者除了已经包含在 EORTC QLQ-C15-PAL 中的那些 S/Ps 之外还经历了哪些其他 S/Ps,我们开发了一种名为 WISP(写入三个症状/问题)的简短仪器来补充这个问卷,允许患者报告 1-3 个额外的 S/Ps 及其严重程度。我们旨在研究 WISP 报告的 S/Ps 的性质、普遍性和严重程度。
这是一项基于登记的研究,数据来自丹麦姑息治疗数据库。这项研究包括在丹麦专门的姑息治疗机构接受治疗的晚期癌症成人患者,他们在 WISP 上报告了 S/Ps。S/Ps 被定性分类,并计算其患病率和严重程度。
在完成 EORTC QLQ-C15-PAL 的 5447 名患者中,有 1788 名(32.8%)患者使用 WISP 报告了至少一种症状/问题。总共报告了 2796 个 S/Ps;24.8%已经被 EORTC QLQ-C15-PAL 涵盖;63.6%是新的,10.1%是诊断,1.6%无法编码。已经涵盖和新的 S/Ps 被分为 61 类。报告的最常见的 S/Ps 依次为疼痛、水肿、头晕、身体或情绪功能受损、咳嗽和出汗。总体而言,85%的 S/Ps 被评为中度至重度。
WISP 仪器通过标准化与个体化相结合,大大提高了 S/Ps 的识别能力。我们建议将其与 EORTC QLQ-C15-PAL 联合使用,用于全面的症状评估,并可能与 EORTC QLQ-C30 联合使用。